Imugene Ltd has released a press release.
Imugene PD1-Vaxx patent extended to 2040
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
- Imugene doses first combination patient in PD1-Vaxx trial
- Imugene secures IND approval for first-in-class onCARlytics trial
- FDA clears Imugene IND for onCARlytics first-in-class study
- onCARlytics with ARTEMIS T cells show anti-tumour activity
Later from Imugene
- HER-Vaxx induced antibodies correlated with tumour reduction
- New Dose Escalation in Phase I Clinical Trial of CHECKvacc
- Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
- Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
- Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene